Guardant Health (GH) said Wednesday it introduced a full suite of immunohistochemistry, or IHC, testing for key biomarkers in all solid tumors, such as lung, breast, gastric and ovarian cancers.
The company said IHC testing detects tumor biomarkers that can be used to determine a tumor's characteristics and identify the most suitable targeted cancer treatment.
The new tests are now available in addition to the Guardant360 Tissue multiomic tumor profiling test, the company said.
Shares of Guardant Health were down more than 4% in recent trading.
Price: 38.19, Change: -1.78, Percent Change: -4.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.